Virus-derived immunostimulatory RNA induces type I IFN-dependent antibodies and T-cell responses during vaccination.
Vaccine
; 36(28): 4039-4045, 2018 06 27.
Article
em En
| MEDLINE
| ID: mdl-29861183
ABSTRACT
Adjuvants potentiate and direct the type of immunity elicited during vaccination. However, there is a shortage of adjuvants that elicit robust type-1 immunity required for the control of intracellular pathogens, including viruses. RNA derived from Sendai virus defective viral genomes (DVGs) stimulates RIG-I-like receptor signaling leading to type-1 immunity during infection. Here, we investigated whether a 268nt DVG-derived oligonucleotide (DDO) functions as a strong type-1 immunity-inducing adjuvant during vaccination against influenza virus. We show that DDO induces robust IgG2c antibody production when used in an inactivated influenza A virus (IAV) vaccine. Additionally, DDO induces Th1 and CD8+ T-cell responses able to protect against heterosubtypic IAV challenge. Interestingly, DDO synergized with AddaVax and skewed the immune response towards type-1 immunity. The adjuvancy of DDO alone and in synergy with AddaVax was heavily dependent on type I interferon signaling. Our data support a critical role for type I interferon in the induction of type-1 immune responses during vaccination and demonstrate that DDO is a type-1 immunity orienting vaccine adjuvant that can be used alone or in synergy with other adjuvants.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vírus da Influenza A
/
RNA Viral
/
Vacinas contra Influenza
/
Linfócitos T
/
Interferon Tipo I
/
Vírus Sendai
/
Anticorpos Antivirais
Limite:
Animals
Idioma:
En
Revista:
Vaccine
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Estados Unidos